Profiel
Mr. Thomas G.
Mechtersheimer is a Chief Executive Officer & Executive Director at neurocare group AG and a Founder at Passion Innovation Group Pty Ltd. He is on the Board of Directors at neurocare group AG.
Mr. Mechtersheimer was previously employed as a Non-Executive Director by Fresenius Kabi Oncology Ltd. and a President-Asia Pacific Region by Fresenius Kabi AG.
Actieve functies van Thomas Mechtersheimer
| Bedrijven | Functie | Begin |
|---|---|---|
Passion Innovation Group Pty Ltd.
Passion Innovation Group Pty Ltd. Financial ConglomeratesFinance Provides investment services to the technology industry | Oprichter | 11-12-2013 |
neurocare group AG
neurocare group AG Packaged SoftwareTechnology Services Operates as a neuromodulation therapy platform to clinical and commercial outcomes | Oprichter | 01-01-2015 |
Eerdere bekende functies van Thomas Mechtersheimer
| Bedrijven | Functie | Einde |
|---|---|---|
| FRESENIUS KABI ONCOLOGY LTD | Directeur/Bestuurslid | - |
Fresenius Kabi AG
Fresenius Kabi AG Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for oncology & autoimmune diseases | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Fresenius Kabi AG
Fresenius Kabi AG Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for oncology & autoimmune diseases | Health Technology |
Fresenius Kabi Oncology Ltd.
Fresenius Kabi Oncology Ltd. Miscellaneous Commercial ServicesCommercial Services Manufactures and markets cancer research and anticancer products | Commercial Services |
Passion Innovation Group Pty Ltd.
Passion Innovation Group Pty Ltd. Financial ConglomeratesFinance Provides investment services to the technology industry | Finance |
neurocare group AG
neurocare group AG Packaged SoftwareTechnology Services Operates as a neuromodulation therapy platform to clinical and commercial outcomes | Technology Services |
















